| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2123976 | European Journal of Cancer | 2010 | 6 Pages |
Abstract
There exist inconsistencies and ambiguities in the conclusions drawn from phase II trials, particularly when results are in the grey zone (greater than H0 but less than HA). This may make the integration of phase II trials in phase III trial development strategies difficult and better understanding of the statistical properties of phase II clinical trials is required.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sabrina Allegro, Gregory R. Pond, Sébastien J. Hotte,